Treating Asymptomatic Patients With Polycythemia Vera
Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Jerry L. Spivak, MD, director of the Center for the Chronic Myeloproliferative Disorders and professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, discusses his key takeaway from his presentation from the Texas Virtual Myeloproliferative Neoplasm Workshop regarding treating patients with polycythemia vera (PV), which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia (ET), particularly among women.
To do the most good for these patients, it is best to stick with the simplest treatment, says Spivak. In patients with no symptoms, it is not as important to reduce the white blood cell or platelet counts.
Women are more at risk for PV compared with men, and they are more likely to have progressed to PV from ET than they are to progress to myelofibrosis from ET. In this case, they are expected to have a good lifespan, Spivak says. However, it is important that patients who are asymptomatic be left alone.
<<View more resources and information from the Texas Virtual MPN Workshop
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
January 23rd 2025The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Read More
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline Gastric/GEJ/Esophageal Cancer
January 23rd 20255-year follow-up results from the phase 3 CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Read More
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
